• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

pH维持时间与糜烂性食管炎愈合率之间关系的数学模型

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates.

作者信息

Howden Colin W, Scarpignato Carmelo, Leifke Eckhard, Mulford Darcy J, Lahu Gezim, Facius Axel, Yuan Yuhong, Hunt Richard

机构信息

University of Tennessee College of Medicine, Memphis, Tennessee, USA.

Department of Health Sciences, United Campus of Malta, Msida, Malta.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2025 Jan;14(1):28-41. doi: 10.1002/psp4.13235. Epub 2024 Sep 19.

DOI:10.1002/psp4.13235
PMID:39297248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11706433/
Abstract

Effective suppression of gastric acid secretion promotes healing of erosive esophagitis. Treatment guidelines recommend proton pump inhibitors (PPIs) and histamine H-receptor antagonists (HRAs). Emerging evidence also supports potassium-competitive acid blockers (P-CABs). The aim was to construct a mathematical model to examine the relationship between pH holding time ratios (HTRs) and erosive esophagitis healing rates with HRAs, PPIs and P-CABs. By literature search, we identified studies of HRAs, PPIs or P-CABs that reported mean pH >4 HTRs at steady state (days 5-8) and erosive esophagitis healing rates after 4 and/or 8 weeks. We aggregated treatments by drug class and developed a non-linear, mixed-effects model to explore the relationship between pH >4 HTRs and healing rates. The pH dataset included 82 studies (4297 participants; 201 dosage arms); healing rate data came from 103 studies (43,417 patients; 196 treatment arms). P-CABs achieved the longest periods with intragastric pH >4, and the highest healing rates after 4 and 8 weeks. The predicted probabilities of achieving ≥90% healing rates at 8 weeks were 74.1% for P-CABs, 17.3% for PPIs and 0% for HRAs. P-CABs provide the longest duration with intragastric pH >4 and, accordingly, the highest healing rates of erosive esophagitis.

摘要

有效抑制胃酸分泌可促进糜烂性食管炎的愈合。治疗指南推荐使用质子泵抑制剂(PPI)和组胺H受体拮抗剂(HRA)。新出现的证据也支持钾竞争性酸阻滞剂(P-CAB)。本研究旨在构建一个数学模型,以研究使用HRA、PPI和P-CAB时的pH维持时间比(HTR)与糜烂性食管炎愈合率之间的关系。通过文献检索,我们确定了有关HRA、PPI或P-CAB的研究,这些研究报告了稳态(第5 - 8天)时平均pH >4的HTR以及4周和/或8周后的糜烂性食管炎愈合率。我们按药物类别汇总治疗方法,并开发了一个非线性混合效应模型,以探索pH >4的HTR与愈合率之间的关系。pH数据集包括82项研究(4297名参与者;201个剂量组);愈合率数据来自103项研究(43417名患者;196个治疗组)。P-CAB使胃内pH >4的时间最长,在4周和8周后的愈合率最高。在8周时达到≥90%愈合率的预测概率,P-CAB为74.1%,PPI为17.3%,HRA为0%。P-CAB使胃内pH >4的持续时间最长,因此糜烂性食管炎的愈合率最高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/3cffe7906f5e/PSP4-14-28-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/9caefa70c54b/PSP4-14-28-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/e80e480fb57c/PSP4-14-28-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/be64e6e9b58f/PSP4-14-28-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/647199c3c825/PSP4-14-28-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/32b89a9150e5/PSP4-14-28-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/3cffe7906f5e/PSP4-14-28-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/9caefa70c54b/PSP4-14-28-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/e80e480fb57c/PSP4-14-28-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/be64e6e9b58f/PSP4-14-28-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/647199c3c825/PSP4-14-28-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/32b89a9150e5/PSP4-14-28-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc6c/11706433/3cffe7906f5e/PSP4-14-28-g006.jpg

相似文献

1
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates.pH维持时间与糜烂性食管炎愈合率之间关系的数学模型
CPT Pharmacometrics Syst Pharmacol. 2025 Jan;14(1):28-41. doi: 10.1002/psp4.13235. Epub 2024 Sep 19.
2
Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis.钾离子竞争性酸阻滞剂和质子泵抑制剂用于糜烂性食管炎愈合的系统评价和网状Meta分析
Therap Adv Gastroenterol. 2024 Jun 19;17:17562848241251567. doi: 10.1177/17562848241251567. eCollection 2024.
3
Importance of pH control in the management of GERD.pH值控制在胃食管反流病管理中的重要性。
Arch Intern Med. 1999 Apr 12;159(7):649-57. doi: 10.1001/archinte.159.7.649.
4
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review.AGA 临床实践更新:将钾离子竞争性酸阻滞剂整合到临床实践中:专家评论。
Gastroenterology. 2024 Nov;167(6):1228-1238. doi: 10.1053/j.gastro.2024.06.038. Epub 2024 Sep 11.
5
The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease.胃食管反流病中pH值控制与愈合及症状缓解之间的关系。
Aliment Pharmacol Ther. 1995;9 Suppl 1:3-7. doi: 10.1111/j.1365-2036.1995.tb00777.x.
6
pH, healing rate, and symptom relief in patients with GERD.胃食管反流病患者的pH值、愈合率及症状缓解情况。
Yale J Biol Med. 1999 Mar-Jun;72(2-3):181-94.
7
Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.组胺2受体拮抗剂与质子泵抑制剂联合使用可增强胃酸抑制作用。
Pharmacotherapy. 2015 Dec;35(12):1124-9. doi: 10.1002/phar.1665. Epub 2015 Dec 1.
8
Novel approaches to inhibition of gastric acid secretion.抑制胃酸分泌的新方法。
Curr Gastroenterol Rep. 2010 Dec;12(6):437-47. doi: 10.1007/s11894-010-0149-5.
9
Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.抑酸药物:对其夜间抑酸效果的系统评价和网络荟萃分析。
Pharmacotherapy. 2024 Feb;44(2):171-183. doi: 10.1002/phar.2899. Epub 2023 Dec 12.
10
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.H2受体拮抗剂与质子泵抑制剂治疗糜烂性食管炎的头对头比较:一项荟萃分析。
World J Gastroenterol. 2005 Jul 14;11(26):4067-77. doi: 10.3748/wjg.v11.i26.4067.

引用本文的文献

1
Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for Eradication: A Network Meta-Analysis.基于钾离子竞争性酸阻滞剂和质子泵抑制剂的铋剂四联疗法根除幽门螺杆菌的疗效和安全性比较:网状Meta分析
Gastro Hep Adv. 2025 May 16;4(9):100705. doi: 10.1016/j.gastha.2025.100705. eCollection 2025.
2
Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.钾离子竞争性酸阻滞剂对经皮冠状动脉介入治疗后接受双联抗血小板治疗患者上消化道出血的影响:一项全国性队列研究
J Gastroenterol Hepatol. 2025 Jul;40(7):1686-1694. doi: 10.1111/jgh.16989. Epub 2025 Apr 27.
3

本文引用的文献

1
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.沃诺拉赞与兰索拉唑治疗糜烂性食管炎的疗效比较:一项随机对照试验的系统评价和荟萃分析。
Indian J Gastroenterol. 2023 Aug;42(4):475-484. doi: 10.1007/s12664-023-01384-2. Epub 2023 Jul 7.
2
Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.随机临床试验:替戈拉赞与兰索拉唑治疗愈合的轻度糜烂性食管炎的维持治疗比较。
Aliment Pharmacol Ther. 2023 Jan;57(1):72-80. doi: 10.1111/apt.17255. Epub 2022 Oct 31.
3
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis.临床试验:新型钾竞争性酸阻滞剂谷氨酸利那普唑与兰索拉唑治疗糜烂性食管炎的剂量探索研究。
Aliment Pharmacol Ther. 2025 May;61(10):1590-1602. doi: 10.1111/apt.70109. Epub 2025 Apr 4.
4
Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.综述文章:胃食管反流样症状的个体化管理——抑酸以外的策略
Aliment Pharmacol Ther. 2025 May;61(9):1437-1446. doi: 10.1111/apt.70115. Epub 2025 Apr 1.
Vonoprazan 与兰索拉唑治疗糜烂性食管炎的愈合和维持愈合:一项随机试验。
Gastroenterology. 2023 Jan;164(1):61-71. doi: 10.1053/j.gastro.2022.09.041. Epub 2022 Oct 10.
4
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.美国受试者中钾竞争性酸阻滞剂 vonoprazan 和质子泵抑制剂兰索拉唑的药效学和药代动力学。
Am J Gastroenterol. 2022 Jul 1;117(7):1158-1161. doi: 10.14309/ajg.0000000000001735. Epub 2022 Mar 16.
5
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.替戈拉赞与沃诺拉赞或埃索美拉唑相比对夜间胃酸的抑制作用。
Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268. Epub 2022 Feb 23.
6
Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.综述文章:钾离子竞争型酸阻滞剂在酸相关疾病治疗中的应用。
Aliment Pharmacol Ther. 2021 Apr;53(7):794-809. doi: 10.1111/apt.16295. Epub 2021 Feb 16.
7
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.长期使用沃克治疗对于控制有症状的质子泵抑制剂抵抗的胃食管反流病有效。
Biomed Rep. 2021 Mar;14(3):32. doi: 10.3892/br.2021.1408. Epub 2021 Feb 1.
8
Editorial: acid suppression with potassium-competitive acid blockers dismissing genotype concerns.社论:使用钾竞争性酸阻滞剂进行抑酸治疗,无需考虑基因型问题。
Aliment Pharmacol Ther. 2021 Jan;53(1):187-188. doi: 10.1111/apt.16139.
9
Advances in the diagnosis and management of gastroesophageal reflux disease.胃食管反流病的诊断和治疗进展。
BMJ. 2020 Nov 23;371:m3786. doi: 10.1136/bmj.m3786.
10
Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.Vonoprazan 与质子泵抑制剂治疗胃食管反流病的疗效和安全性的直接比较:系统评价和荟萃分析。
Dig Dis Sci. 2021 Jan;66(1):19-28. doi: 10.1007/s10620-020-06141-5. Epub 2020 Feb 24.